ClinicalTrials.gg
CompletedNCT06661681Updated Sep 25, 2026

Cognitive Functional Therapy for Treating Individuals With Chronic Shoulder Pain

An interventional study of Cognitive Functional Therapy (CFT) and Therapeutic exercises group in Chronic Shoulder Pain, Exercise Therapy and Psychosocial Rehabilitation, sponsored by Federal University of Paraíba. Completed at 1 site in Brazil. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Federal University of Paraíba · Not applicable, Interventional, and Treatment

How we know

Updated Sep 25, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Shoulder Pain with a site in Brazil — 2 open to participants now, 2 under way, none of them phase 3. Shoulder Pain · Brazil.

Enrollment
8th of 21
72 · median 64
Started
2025
with 2 others
No phase
19 of 21
2 open now
Registered
19th of 21
by date
Lead sponsor
2 of 21
Federal University of Paraíba

Among the 21 studies in Shoulder Pain with a site in Brazil, this one is the 8th largest by enrollment, is one of 3 that started in 2025, is one of 19 with no phase, and was the 19th registered.

Shoulder Pain

738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.

Browse Shoulder Pain studies →

Open to participants now

2 of the 21 studies in Shoulder Pain with a site in Brazil are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Shoulder Pain with a site in Brazil, or all of them as a file.
02

Study summary

Shoulder pain is a debilitating musculoskeletal condition with functional, physical, and psychological impacts. Interventions for chronic shoulder pain should address the biopsychosocial model, with Cognitive Functional Therapy emerging as a promising physiotherapy approach. Cognitive Functional Therapy approaches the multidimensional nature of pain, integrating physical and cognitive aspects.

The aim of this randomized controlled trial is to compare the effects of Cognitive Functional Therapy with therapeutic exercise on biological aspects of pain (pain intensity, disability, function, perception of improvement/deterioration, and central pain processing), and psychosocial aspects of pain (sleep quality, self-efficacy, and biopsychosocial factors). The hypothesis of this study is that CFT will lead to greater improvements in these outcomes compared to therapeutic exercise.

Read the detailed description

This will be a randomized controlled trial, single-blinded with two parallel groups. Seventy-two individuals with chronic shoulder pain will be randomly assigned to one of two groups: CFT or Therapeutic exercises. The interventions will last eight weeks, with the CFT group receiving therapy once a week and the therapeutic exercise group receiving sessions twice weekly. The primary outcomes will be pain intensity and disability, while the secondary outcomes will include function, self-efficacy, sleep quality, biopsychosocial factors, perception of improvement/deterioration, and central pain processing.

03

Conditions studied

  • Chronic Shoulder Pain
  • Exercise Therapy
  • Psychosocial Rehabilitation

Keywords

  • Shoulder pain
  • Subacromial pain
  • Rotator cuff related shoulder pain
  • Shoulder Impingement
  • Chronic pain
  • Psychosocial
  • Rehabilitation
  • Biopsychosocial
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women;
  • Age between 18 and 60 years;
  • Presence of shoulder pain for more than 3 months;
  • Pain intensity of 4 points or more on the 11-point Numeric Pain Rating Scale.
  • High level of disability or moderate level of irritability.

Exclusion criteria

Exclusion Criteria:

  • History of fracture or surgery of the clavicle, scapula, and/or humerus, surgical stabilization or rotator cuff repair;
  • History of dislocation, instability (positive sulcus sign or apprehension test), and/or rotator cuff tear (positive drop arm test);
  • Adhesive capsulitis verified by the presence of gradual onset pain associated with stiffness and reduced passive and active mobility;
  • Ongoing pregnancy;
  • Reproduction of shoulder pain radiating to the entire upper limb during cervical or thoracic spine tests (positive Spurling test);
  • Neurological or systemic diseases that may alter muscle strength and sensitivity such as rheumatoid arthritis, fibromyalgia, lupus, gout, and diabetes;
  • injection in the shoulder region in the last 3 months;
  • Physiotherapy treatment in the last 6 months.
  • Active treatment for cancer
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Cognitive Functional Therapy

    Cognitive Functional Therapy (CFT) will be conducted weekly in sessions lasting approximately 60 minutes over 8 weeks.

    Behavioral: Cognitive Functional Therapy (CFT)

  • Active comparator
    Therapeutic exercises group

    Individuals assigned to this group will be treated twice a week for eight weeks, wich each session will last approximately 40 to 60 minutes.

    Other: Therapeutic exercises group

Interventions

  • BehavioralCognitive Functional Therapy (CFT)

    Cognitive Functional Therapy (CFT) is underpinned by a strong therapeutic alliance, active listening, and motivational interviewing style, covering the following domains: i) Making sense of pain involves discussing the multidimensional nature of persistent pain, as well as the beliefs, emotions, and behaviors that can perpetuate the vicious cycle of pain and disability. ii) Exposure with control involves a functional training designed to normalize maladaptive and provocative postural and movement behaviors, where individuals will learn strategies to improve their body awareness and control and modify postures and tasks commonly associated with pain. iii) Lifestyle change aims to help patients embrace a healthy lifestyle, which will include promoting a gradual increase in physical activity, sleep hygiene counseling, stress management strategies, and social re-engagement.

    Also known as: CFT

  • OtherTherapeutic exercises group

    Each session will include stretching exercises targeting the following muscles i) Upper trapezius; ii) Pectoralis minor; iii) Posterior shoulder region, and strengthening exercises targeting the following muscles i) Lower trapezius, ii) Middle trapezius, iii) Serratus punch exercise, iv) Shoulder external rotators, and v) Shoulder internal rotators.

06

What researchers measure

Primary outcomes

  1. Pain intensity: Numerical Pain Rating Scale (NPRS)

    The pain intensity will be measured with 11 point - Numerical Rating Pain Scale (NPRS) with scores ranging from 0 (no pain) to 10 (maximum pain). Higher scores indicate greater pain intensity.

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

  2. Disability: Shoulder Pain and Disability Index (SPADI)

    Disability will be assessed with Shoulder Pain and Disability Index (SPADI). which is composed of 13 questions related to two domains: disability (eight items) and pain (five items). The final score ranges from 0 to 100, with higher scores indicating greater shoulder disability

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

Secondary outcomes

  1. Shoulder function: Patient Specific Functional Scale

    Shoulder functional ability will be measured with Patient Specific Functional Scale. The individuals will select three to five important activities that are challenging to perform due to shoulder pain. For each reported activity, the individual will score on an 11-point scale, where 0 is (unable to perform the activity) and 10 is (able to perform the activity at the level prior to the injury). Score ranges from 0 (unable to perform) to 10 (able to perform at preinjury level). Higher score means better function.

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

  2. Self-efficacy: Pain Self-Efficacy Questionnaire (PSEQ)

    Self-efficacy will be assessed with Pain Self-Efficacy Questionnaire (PSEQ) will be used to assess, which is composed of of 10 items. The total score ranges from 0 to 60 points, with the higher score indicating greater self-efficacy.

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

  3. Sleep quality: Pittsburgh Sleep Quality Index (PSQI)

    Sleep quality will be assessed with Pittsburgh Sleep Quality Index (PSQI), which is composed of 19 items, resulting in a total score ranging from 0 to 21, and covering 7 domains: (1) subjective sleep quality, (2) sleep latency, (3) sleep duration, (4) habitual sleep efficiency, (5) sleep disturbance, (6) medication use and (7) dysfunction during the day. The total score ranges from 0 to 21, with higher scores indicating worse sleep quality.

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

  4. Biopsychosocial Aspects: Brief Screening Questions for Biopsychosocial Aspects

    Biopsychosocial Aspects will be assessed with the Brief Screening Questions for Biopsychosocial, which is composed of six questions covering five domains: anxiety, kinesiophobia, stress, catastrophizing, and depression. The scores for each question range from 0 to 10, with higher scores indicating worse symptoms.

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

  5. Perception of improvement/deterioration over time: Global Rating of Change Scale

    The individual's perception of improvement/deterioration over time will be measured with the Global Rating of Change Scale, which ranges from -7 to 7, with positive and higher scores indicating a greater perception of health improvement, negative and lower scores indicating a worsening perception of health, and a score of zero representing no change.

    Time frame: 4-week, at the end of treatment (8-week), and 12-week follow-up

  6. Central pain processing: Pressure Pain Threshold (PPT)

    Pressure Pain Threshold (PPT) is defined as the minimum amount of pressure that triggers the first sensation of pain. Pressure Pain Threshold will be measured by a digital pressure algometer (AlgoMed ®, Hӧrby, Sweden) with 1 cm2 circular rubber probe tip and a pressure rate of approximately 40 kPa/s. The Pressure Pain Threshold test will be performed at the acromion and muscle bellies of the deltoid, upper trapezius, and tibialis anterior.

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

  7. Central pain processing: Temporal summation

    Temporal summation refers to increased perceived pain from repetitive nociceptive stimuli at the same site, which is related to the modulation mechanism occurring in second-order sensory neurons in the spinal cord. The temporal summation will be measured at the deltoid and tibialis anterior. Sequential stimulation will involve 10 pressure stimuli at the pre-established Pressure Pain Threshold level, with a one-second interval between stimuli. Each pressure increment will be approximately 40 kPa/s. After the first and tenth stimuli, participants will rate their pain intensity using the Numerical Rating Pain Scale (NPRS) with scores ranging from 0 (no pain) to 10 (maximum pain), and higher scores indicate greater pain intensity. The temporal summation will be quantified by subtracting the pain intensity rating for the first stimulus from the pain rating for the tenth.

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

  8. Central pain processing: Conditioned Pain Modulation

    Conditioned Pain Modulation (CPM) refers to the central nervous system's ability to inhibit pain through mechanisms related to endogenous descending inhibition. Individuals will immerse their hand in a cold-water bath for 2 minutes. Pressure Pain Threshold (PPT) at the deltoid of the affected (or most affected) side will be assessed at baseline, during immersion (after 30, 60, and 90 seconds), and after immersion (immediately post-withdrawal and at 30 and 60 seconds after withdrawal). Participants will rate their pain intensity on the Numerical Rating Pain Scale (NPRS) with scores ranging from 0 (no pain) to 10 (maximum pain), and higher scores indicate greater pain intensity, every 30 seconds from immersion until hand withdrawal, and 30 and 60 seconds after withdrawal. CPM will be calculated by subtracting the PPT of the deltoid from PPT measures during and after Conditioned Pain Modulation.

    Time frame: Baseline, 4-week, at the end of treatment (8-week), and 12-week follow-up

07

Study locations

1 site
  • Federal University of Paraíba
    João Pessoa, Paraíba 58051-970, Brazil
08

References and documents

Individual participant data

Plan to share: Yes — The individual participant data will be shared under request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: baseline, 4th week, end of treatment (8th week), and 12th-week follow-up.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Dec 2025, 10 months.

Of 351 non-industry interventional studies with no phase under Shoulder Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 10 months is close to that.

Counting every sponsor, half of 356 studies reached it within 11 months; a quarter within 4 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Jun 2026 → Dec 2025 and completion Nov 2026 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2024
First posted
Oct 28, 2024
StartActual
Feb 17, 2025
Primary completionActual
Dec 31, 2025was Jun 2026
CompletionActual
Dec 31, 2025was Nov 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 25, 2026
Primary completion
Jun 25, 2026→Dec 31, 2025 (actual)
Sep 25, 2026
Study completion
Nov 25, 2026→Dec 31, 2025 (actual)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Recruiting→Completed
    Primary completion Jun 25, 2026→Dec 31, 2025 (now actual)
    Study completion Nov 25, 2026→Dec 31, 2025 (now actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06661681
Lead sponsor
Federal University of Paraíba
Responsible party
Danilo Harudy Kamonseki (Professor, Federal University of Paraíba) — Principal investigator
First posted
Oct 28, 2024
Start date
Feb 17, 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Sep 25, 2026

Study contacts

Danilo H Kamonseki, PhD
principal investigator · Universidade Federal da Paraíba

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion